Low Back Pain

Last updated 31 May 2026 · Musculoskeletal

📋 Key Information Summary

📋

Low back pain (LBP) is the leading cause of disability worldwide; lifetime prevalence in Australia is approximately 80%, with peak incidence in working-age adults 25–55 years.
Over 90% of LBP presentations in Australian general practice are non-specific (mechanical) — no identifiable structural pathology can be pinpointed.
Use the diagnostic triage model to classify LBP into: (1) non-specific mechanical, (2) radicular/specific spinal pathology, or (3) serious/systemic pathology (cauda equina syndrome, malignancy, infection, fracture).
Red flags (age <20 or >55 onset, unexplained weight loss, progressive neurological deficit, saddle anaesthesia, bladder/bowel dysfunction, history of malignancy, IV drug use, immunosuppression, fever, structural deformity) mandate urgent imaging and specialist referral.
Yellow flags (fear-avoidance beliefs, catastrophising, workplace dissatisfaction, depression, compensation claims) are the strongest predictors of chronicity and disability — screen early and address proactively.
Inflammatory back pain (insidious onset, age <40, morning stiffness >30 min, improvement with exercise, nocturnal pain waking from sleep) raises suspicion for axial spondyloarthritis — request HLA-B27 and SIJ imaging.
Mechanical back pain worsens with activity, improves with rest, and has no systemic features — most cases self-resolve within 6–12 weeks with reassurance and active management.
Routine imaging (X-ray, CT, MRI) is not indicated in the first 4–6 weeks unless red flags are present — incidental findings are common and may lead to unnecessary interventions.
First-line pharmacotherapy: regular paracetamol (despite recent evidence debates) and/or short courses of NSAIDs (e.g., naproxen 250–500 mg BD with PPI cover); avoid opioids wherever possible.
Active management — maintaining activity, avoiding bed rest, structured physiotherapy, and graduated return to work — is the cornerstone of evidence-based LBP care in Australia.
Aboriginal and Torres Strait Islander Australians experience higher LBP prevalence, greater disability burden, and reduced access to musculoskeletal services — culturally safe, community-based approaches are essential.

Introduction & Australian Epidemiology

Low back pain (LBP) is the most common musculoskeletal presentation in Australian general practice, accounting for an estimated 3–4 million consultations annually. It is the leading cause of years lived with disability (YLDs) in Australia and globally, and a leading cause of work absenteeism and workers' compensation claims.

The Australian Institute of Health and Welfare (AIHW) reports that musculoskeletal conditions — dominated by LBP — affect over 7 million Australians. The 2022 Global Burden of Disease study ranked LBP as the number-one condition for disability-adjusted life years (DALYs) in Australia across all age groups.

Epidemiological Measure	Australian Data
Lifetime prevalence	~80% (any episode)
Point prevalence	~15–25% at any given time
Peak age group	25–55 years (working age)
Annual GP presentations	~3–4 million encounters
Chronicity rate (pain >3 months)	~10–15% of initial episodes
Workers' compensation	Leading musculoskeletal claim nationally
Economic burden	>.8 billion annually (direct + indirect)

A comprehensive approach to LBP in general practice requires accurate diagnostic triage, identification of red and yellow flags, rational investigation, and patient-centred, active management. Most presentations are self-limiting, but a minority develop chronic pain with significant personal, social, and economic consequences.

The Australian Commission on Safety and Quality in Health Care (ACSQHC) has published specific clinical care standards for LBP, emphasising evidence-based care, shared decision-making, and de-escalation of low-value interventions (unnecessary imaging, opioids, bed rest).

Causes & Anatomical Concepts

Anatomical Overview

The lumbar spine (L1–L5) bears the majority of axial load and is the most common site of back pain. The lumbosacral junction (L5–S1) experiences the greatest biomechanical stress due to its transitional position.

Structure	Pain Generator Role	Clinical Features
Intervertebral disc	Most common source (~40%); annular tears, degenerative disc disease, disc herniation	Central or paracentral pain; worsened by flexion, sitting, Valsalva
Facet (zygapophyseal) joints	~10–15% of chronic LBP; arthropathy, synovitis	Posterior pain; worsened by extension and rotation; referred to buttock/thigh
Sacroiliac joint	~10–25% of chronic LBP; sacroiliitis (inflammatory or post-traumatic)	Buttock/PSIS pain; worsened by single-leg stance, FABER test
Lumbar nerve roots	Disc herniation, spinal stenosis, foraminal narrowing	Radiculopathy — dermatomal pain, paraesthesia, weakness, positive SLR
Paraspinal muscles & fascia	Myofascial trigger points; guarding/bracing secondary to other pathology	Diffuse, aching pain; palpable taut bands; stiffness after rest
Vertebral body	Fracture (osteoporotic, traumatic); metastasis; infection	Constant pain, unrelieved by position change; tenderness over spinous process
Spinal cord / cauda equina	Cauda equina syndrome (disc, tumour, abscess)	Saddle anaesthesia, bladder/bowel dysfunction, bilateral leg weakness — surgical emergency
Visceral referred pain	Aortic aneurysm, renal colic, pancreatitis, endometriosis, pelvic pathology	Non-mechanical pattern; does not change with spinal movement; associated visceral symptoms

Common Causes by Category

The following classification guides the Australian general practitioner through the diagnostic triage model recommended by the ACSQHC and RACGP:

ℹ️

Non-specific (mechanical) LBP — ~90% of presentations: No identifiable structural pathology despite thorough assessment. Attributed to intervertebral disc, facet joint, sacroiliac joint, or myofascial structures. Self-limiting in most cases.

Specific Spinal Pathology (≈1–5%)

Disc herniation / radiculopathy: Nucleus pulposus extrusion compressing nerve root; most common at L4–5 and L5–S1. Unilateral leg pain > back pain; positive straight leg raise (SLR); dermatomal sensory loss or motor weakness.
Spinal stenosis: Degenerative narrowing of central canal or neuroforamina; neurogenic claudication — leg pain/bilateral symptoms worsened by walking and extension, relieved by sitting/flexion. Common in adults >60 years.
Spondylolisthesis: Anterior slippage of one vertebra on another (isthmic defect or degenerative). Mechanical back pain ± radiculopathy; step deformity on palpation.
Vertebral compression fracture: Osteoporotic (elderly, steroid use) or traumatic; focal tenderness; sudden onset after minimal trauma.
Axial spondyloarthritis (ankylosing spondylitis / nr-axSpA): Inflammatory back pain in young adults; HLA-B27 associated; sacroiliitis on MRI/CT.

Serious Spinal Pathology (≈1–2%)

🚨

These conditions require urgent recognition and intervention:

Cauda equina syndrome: Surgical emergency — saddle anaesthesia, bilateral sciatica, urinary retention or overflow incontinence, loss of anal tone.
Vertebral osteomyelitis / discitis / epidural abscess: Persistent unremitting pain; fever; raised ESR/CRP; risk factors (IVDU, recent spinal procedure, immunosuppression).
Primary or metastatic spinal malignancy: Unremitting night pain; weight loss; history of cancer; age >55 new onset.
Cauda equina / conus medullaris compression: Tumour (primary CNS, metastatic, lymphoma), large disc herniation, abscess.

Non-Spinal Causes of Back Pain

Abdominal aortic aneurysm (pulsatile abdominal mass; male >65 — screen with ultrasound)
Renal colic / pyelonephritis
Pancreatitis (epigastric pain radiating to back)
Pelvic pathology (endometriosis, ovarian cyst, ectopic pregnancy)
Herpes zoster (prodromal dermatomal pain preceding rash by 2–5 days)
Hip pathology (referred pain to buttock/lower back)

Diagnostic Model & Probability Diagnosis

The Diagnostic Triage Model

The internationally recommended (and Australian-adopted) approach to LBP classifies all presentations into one of three categories. This triage guides investigation urgency, treatment pathway, and disposition.

Non-Specific (Mechanical) LBP

~90% of cases. No clear structural cause identified. Pain is mechanical (worsens with certain movements, improves with rest). No red flags. Neurological examination normal. Managed conservatively in primary care.

Radicular Pain / Nerve Root Compression

~5–10% of cases. Sciatica — pain radiating below the knee in a dermatomal distribution. Positive SLR test. May have neurological deficits (sensory, motor, reflex). Consider imaging if symptoms persist >6 weeks or deficits progress.

Serious / Systemic Spinal Pathology

~1–2% of cases. Cauda equina syndrome, malignancy, infection, fracture. Red flags present. Urgent investigation and specialist referral required. Do not delay.

Probability Diagnosis — Clinical Reasoning Approach

In Australian general practice, the pre-test probability of a diagnosis is shaped by prevalence, history, and examination findings. Bayesian reasoning should guide whether further investigation is warranted.

Diagnosis	Estimated Probability	Key Clinical Clues
Non-specific mechanical LBP	~85–90%	Age 20–55; activity-related; normal neuro exam; no red flags
Disc herniation with radiculopathy	~3–5%	Leg pain > back pain; SLR positive; dermatomal distribution
Spinal stenosis (neurogenic claudication)	~3% (increases with age >60)	Bilateral leg symptoms; relieved by flexion/sitting; pseudoclaudication
Vertebral fracture	~1–4%	Elderly; osteoporosis; steroid use; minor trauma; focal spinous tenderness
Axial spondyloarthritis	~1–5% of chronic LBP in <45 years	Inflammatory features; HLA-B27; sacroiliitis; extra-articular features (psoriasis, uveitis, IBD)
Malignancy (primary / metastatic)	~0.5–1%	Age >55; unremitting night pain; weight loss; cancer history
Infection (osteomyelitis / discitis)	<0.5%	Fever; IVDU; immunosuppression; recent spinal procedure; raised inflammatory markers
Cauda equina syndrome	<0.1%	Saddle anaesthesia; bilateral leg weakness; bladder/bowel dysfunction
Sacroiliac joint dysfunction	~10–25% (chronic LBP)	Buttock/PSIS pain; positive provocation tests (distraction, compression, FABER, thigh thrust, Gaenslen)
Non-spinal (referred) pain	~2%	No mechanical pattern; visceral symptoms; does not change with movement

✅

Clinical pearl: The history alone establishes the diagnosis in ~80% of LBP presentations. The physical examination narrows the differential and identifies red flags. Investigations confirm specific diagnoses — they do not establish them.

Duration-Based Classification

Acute

<6 weeks

Most common. Usually self-limiting. 80–90% resolve within 6 weeks regardless of treatment. Focus on reassurance and active management.

Setting: Primary care (GP)

Subacute

6–12 weeks

Persistent symptoms. Re-evaluate for missed red/yellow flags. Consider imaging if not done. Intensify physiotherapy. Multidisciplinary input may be needed.

Setting: GP + allied health ± specialist

Chronic

>12 weeks

10–15% of acute episodes become chronic. Biopsychosocial model essential. Yellow flags drive disability. Multidisciplinary pain management. Avoid escalation of opioids/imaging.

Setting: Multidisciplinary pain service

Red Flags & Yellow Flags

Red Flags — Serious Spinal Pathology

Red flags are clinical features that raise the probability of serious underlying pathology (malignancy, infection, fracture, cauda equina syndrome). Their presence should prompt urgent investigation — not automatic imaging in all LBP.

🚨

Cauda equina syndrome is a surgical emergency. Any patient with saddle anaesthesia, bilateral sciatica, new urinary retention or incontinence, or loss of anal tone requires immediate MRI and emergent neurosurgical consultation. Do not delay for imaging if clinical suspicion is high.

Red Flag	Concern	Recommended Action
Age of onset <20 years or >55 years	Malignancy, spondyloarthropathy, AAA, fracture	Low threshold for imaging; consider ESR/CRP
Unexplained weight loss	Malignancy, infection	Bloods (FBC, ESR, CRP, LFTs, calcium, protein electrophoresis); MRI
Constant, progressive, unremitting pain	Malignancy, infection, fracture	Does not change with posture/movement — urgent MRI
Nocturnal pain — waking from sleep	Malignancy, infection, spondyloarthropathy	Bloods + MRI; consider spondyloarthritis workup if age <45
History of malignancy	Spinal metastases	Urgent MRI with contrast; contact treating oncologist
Fever / rigors	Vertebral osteomyelitis, discitis, epidural abscess	Blood cultures, ESR/CRP, FBC; MRI; IV antibiotics
Immunosuppression (HIV, transplant, biologics, chemotherapy)	Atypical infection, opportunistic organisms	Low threshold for MRI; broad microbiological workup
IV drug use	Spinal epidural abscess, discitis, endocarditis	Blood cultures, ESR/CRP, echocardiography; MRI; infectious diseases referral
Prolonged corticosteroid use	Osteoporotic vertebral compression fracture	Plain X-ray; DEXA scan; consider MRI if X-ray equivocal
Structural deformity (scoliosis, kyphosis)	Underlying bony pathology, Scheuermann's, fracture	Imaging as indicated; orthopaedic/spinal referral
Saddle anaesthesia	Cauda equina syndrome	Emergency MRI; neurosurgical referral
Bladder / bowel dysfunction (retention, incontinence)	Cauda equina syndrome	Emergency MRI; post-void residual; urgent surgical review
Progressive neurological deficit	Cord/cauda compression, expanding lesion	Urgent MRI; neurosurgical/orthopaedic spinal referral
Major motor weakness (foot drop, bilateral)	Significant nerve root compression	Urgent MRI; surgical opinion within 24–48 hours if worsening

⚠️

Sensitivity vs specificity: Individual red flags have high sensitivity but low specificity for serious pathology. The presence of a single red flag increases the probability marginally — it is the combination of multiple red flags, or a single very concerning feature (e.g., cauda equina symptoms), that mandates urgent action. Use clinical judgement.

Yellow Flags — Psychosocial Risk Factors for Chronicity

Yellow flags are psychosocial factors that predict the transition from acute to chronic LBP and persistent disability. Evidence consistently demonstrates that yellow flags are more predictive of poor outcomes than clinical or imaging findings. Early identification and intervention are critical.

Domain	Yellow Flag Examples	Assessment Strategy
Beliefs & attitudes	Fear-avoidance behaviour; belief that pain = harm; catastrophising; expectation of passive treatments only	Ask: "What do you think is causing your pain?" "Are you worried about doing permanent damage?"
Emotional state	Depression; anxiety; low mood; irritability; hopelessness	PHQ-9, GAD-7, K10; "How has the pain affected your mood?"
Work & compensation	Dissatisfaction with job; workers' compensation claim; perceived injustice; prolonged time off work	"Do you have a current workers' compensation claim?" "How do you feel about your job?"
Social context	Social isolation; lack of social support; family/relationship conflict; financial stress	Social history; "Who is supporting you at home?"
Behavioural	Over-reliance on rest; avoidance of activity; excessive healthcare seeking; medication overuse	Activity diary; "What activities have you stopped doing?"

✅

Screening tools for yellow flags (Australian context):

Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) — validated screening tool for acute/subacute LBP; score >105/210 predicts poor outcome
STarT Back Screening Tool — classifies patients into low, medium, high risk of persistent disability; guides matched care pathways
Pain Catastrophising Scale (PCS) — measures rumination, magnification, helplessness
Tampa Scale of Kinesiophobia (TSK) — measures fear of movement/(re)injury

Inflammatory vs Mechanical Pain Comparison

Distinguishing inflammatory back pain from mechanical back pain is one of the most important diagnostic tasks in LBP assessment. Failure to identify inflammatory aetiology — particularly axial spondyloarthritis (axSpA) — leads to diagnostic delays averaging 7–10 years, progressive structural damage, and avoidable disability.

⚠️

Axial spondyloarthritis prevalence: Estimated prevalence in Australia is 0.5–1.5% of the population (similar to rheumatoid arthritis). Up to 5% of young adults (<45 years) presenting to GP with chronic LBP may have undiagnosed axSpA. Early referral to rheumatology improves outcomes with modern biologic therapies (TNF inhibitors, IL-17 inhibitors, JAK inhibitors).

Inflammatory vs Mechanical — Feature Comparison

Feature	Inflammatory Back Pain	Mechanical Back Pain
Age of onset	<40 years (typically 15–30)	Any age; peak 25–55
Onset	Insidious; gradual over weeks–months	Often acute; linked to event/strain
Duration of symptoms	>3 months (chronic from outset)	Often <6 weeks (acute); may recur
Morning stiffness	>30 minutes (often 1–2 hours); improves with movement	<30 minutes (brief); stiffness after rest
Effect of rest	Worsens with rest/inactivity	Improves with rest
Effect of exercise	Improves with movement and exercise	Worsens with activity/exertion
Nocturnal pain	Yes — wakes in second half of night; improves on getting up	Usually absent unless severe; not typically nocturnal wakening
Response to NSAIDs	Good — often dramatic (>70% improvement)	Variable; partial relief
Peripheral joint involvement	Common — asymmetric oligoarthritis (knees, ankles), enthesitis, dactylitis	Absent (isolated lumbar spine)
Extra-articular features	Anterior uveitis, psoriasis, inflammatory bowel disease, urethritis	Absent
Family history	First-degree relative with axSpA, psoriasis, IBD, or reactive arthritis	No specific pattern
HLA-B27	Positive in ~80–90% of ankylosing spondylitis; ~50–60% of nr-axSpA	Population prevalence (~6–8% in Caucasians)
Inflammatory markers	CRP/ESR elevated in ~50–60% (may be normal in nr-axSpA)	Normal
Sacroiliac joint imaging	MRI: bone marrow oedema (active sacroiliitis); X-ray: sclerosis, erosions, fusion (late)	Normal (or age-related degenerative changes only)

ASAS Criteria for Inflammatory Back Pain (Clinical Features)

The Assessment of SpondyloArthritis international Society (ASAS) defines inflammatory back pain by the presence of ≥4 of 5 of the following criteria (sensitivity 77%, specificity 91%):

Age of onset <40 years
Insidious onset
Improvement with exercise
No improvement with rest
Pain at night (with improvement upon getting up)

ASAS Classification Criteria for Axial Spondyloarthritis

For patients with chronic back pain (≥3 months) and age at onset <45 years:

Imaging Arm

Sacroiliitis on imaging (MRI or X-ray) PLUS ≥1 SpA feature

Clinical Arm

HLA-B27 positive PLUS ≥2 other SpA features

SpA features include: inflammatory back pain, arthritis, enthesitis (heel), uveitis, dactylitis, psoriasis, Crohn's/colitis, good response to NSAIDs, family history of SpA, elevated CRP, HLA-B27 positivity.

ℹ️

Australian GP action: If a patient <45 years presents with chronic LBP (>3 months) and any features of inflammatory back pain, request HLA-B27, CRP/ESR, and MRI of the sacroiliac joints (MRI is preferred over plain X-ray for early disease). Refer to rheumatology for definitive assessment.

Investigations

Investigation in LBP should be guided by the clinical presentation and the diagnostic triage model. Routine imaging in the absence of red flags is a major source of low-value care in Australia — the Choosing Wisely Australia initiative explicitly recommends against it.

When NOT to Image

⚠️

Do not request imaging in the first 4–6 weeks of non-specific LBP without red flags. Incidental findings on MRI (disc bulges, degenerative changes, Schmorl's nodes) are present in up to 60–80% of asymptomatic individuals and may lead to unnecessary anxiety, further investigation, and surgery. This is one of the most important evidence-based recommendations in LBP management.

Investigations by Clinical Scenario

Essential Thorough history and physical examination The single most important "investigation." Establishes diagnosis in ~80% of cases. Includes neurological examination (myotomes, dermatomes, reflexes), SLR test, crossed SLR, and screening for red flags.

Available FBC, ESR, CRP Request if red flags present (infection, malignancy) or inflammatory back pain suspected. ESR >25 mm/hr or CRP >10 mg/L raises suspicion for inflammatory or infective pathology. MBS items 65070, 65090.

Available HLA-B27 Request when inflammatory back pain features present in a patient <45 years. Positive in ~80–90% of ankylosing spondylitis. Not diagnostic alone — requires clinical context. MBS item 71137.

Available Serum protein electrophoresis / Bence Jones protein If multiple myeloma suspected (back pain + anaemia + raised calcium + renal impairment in patient >50 years). MBS items 69300, 69303.

Available Plain lumbar spine X-ray (AP + lateral) Only if fracture, spondylolisthesis, or structural deformity suspected. Not recommended as routine first-line investigation in non-specific LBP. Low sensitivity for early sacroiliitis. MBS item 57912.

Referral MRI lumbar spine / sacroiliac joints Gold standard for soft tissue pathology, nerve root compression, cauda equina, and sacroiliitis. No radiation. Request urgently for cauda equina syndrome, suspected malignancy, or infection. For inflammatory back pain, MRI SIJ (STIR + T1 sequences) is preferred. MBS items 63109, 63112.

Referral CT lumbar spine Better bony detail than MRI; useful for complex fractures. Higher radiation dose. Not first-line for disc/nerve pathology. Usually requested by specialist. MBS item 56104.

Specialist Bone densitometry (DEXA scan) If osteoporotic fracture suspected. Request in postmenopausal women, men >70, or patients on long-term corticosteroids with vertebral fracture on imaging. MBS item 12322.

Specialist Nerve conduction studies / EMG Distinguish radiculopathy from peripheral neuropathy or plexopathy. Usually requested by neurologist or spinal surgeon when diagnosis is unclear.

Common Incidental Findings on MRI (Asymptomatic Individuals)

Finding	Prevalence (Asymptomatic, Age 20–60)
Disc degeneration	~37% (20 y/o) to ~96% (60 y/o)
Disc bulge	~30% (20 y/o) to ~60% (60 y/o)
Disc protrusion	~19% at age 20; ~29% at age 60
Annular fissure / tear	~19%
Facet joint degeneration	~36% (age 40+)
Schmorl's nodes	~19%
Spondylolisthesis (Grade I)	~4–6%

ℹ️

Communication tip: When MRI findings are incidental, explain to the patient: "These changes are like grey hairs of the spine — they occur with age in almost everyone and don't determine your pain or prognosis." This reframing is essential to prevent catastrophising and unnecessary surgical escalation.

Management

First Principles

Reassurance

Explain that LBP is common, rarely serious, and usually resolves. Explain that imaging is not needed and can cause harm through labelling. Reinforce that pain ≠ damage.

Stay Active

Advise against bed rest (beyond 48 hours). Encourage continuation of normal activities as tolerated. "Hurt does not equal harm." Graduated return to work is therapeutic.

Simple Analgesia

Paracetamol (regular dose) and/or NSAIDs (short course). Avoid opioids. Consider heat therapy. Avoid muscle relaxants routinely due to sedation risk.

Active Therapies

Physiotherapy / exercise therapy is first-line treatment for persistent LBP. Manual therapy may provide short-term benefit. Avoid passive therapies (TENS, ultrasound, traction) without active component.

Address Yellow Flags

Identify and address psychosocial barriers early. Cognitive behavioural therapy (CBT), pain education, graded activity programs. Referral to psychologist if depression/anxiety present.

Pharmacotherapy

💊

Paracetamol

Panadol® · Dymadon® · Paralgin®

Adult dose 500–1000 mg PO every 4–6 hours; max 4 g/day (2 g/day if hepatic impairment or chronic alcohol use)

Paediatric dose 15 mg/kg PO every 4–6 hours; max 60 mg/kg/day

Route Oral (also available IV, PR)

Duration As needed; regularly for first 1–2 weeks, then PRN

Renal adjustment Use with caution in severe CKD; no specific dose reduction required

Hepatic adjustment Max 2 g/day in hepatic impairment; avoid in severe liver disease

PBS status ✔ PBS General Benefit

Notes Recent evidence (PACE trial 2014) questioned efficacy vs placebo for LBP, but remains recommended first-line given safety profile. Combination with NSAID may be more effective than either alone.

💊

Naproxen

Naprosyn® · Inza® · Synflex®

Adult dose 250–500 mg PO BD with food; max 1 g/day

Paediatric dose 5–7 mg/kg BD (juvenile arthritis); not routinely used for LBP in children

Route Oral (also available PR suppository 500 mg)

Duration Short course — 7–14 days; reassess need

Renal adjustment Avoid if eGFR <30 mL/min; use with caution in CKD stage 3

Hepatic adjustment Avoid in severe hepatic impairment; reduce dose in moderate impairment

PBS status ✔ PBS General Benefit

Notes Preferred NSAID — lower cardiovascular risk profile compared to diclofenac/COX-2 inhibitors (FDA/MHRA warnings). Co-prescribe PPI (omeprazole 20 mg daily) if risk factors for GI bleeding (>65, history of GI ulcer, concurrent anticoagulant/steroid).

💊

Ibuprofen

Nurofen® · Brufen®

Adult dose 200–400 mg PO TDS–QID with food; max 1.2 g/day (OTC); 2.4 g/day (prescription)

Duration Short course — 7–14 days

Renal adjustment Avoid if eGFR <30 mL/min

PBS status ✔ PBS General Benefit

Notes Available OTC; lower GI risk than many NSAIDs at standard doses. Shorter duration of action requires more frequent dosing. May be preferred for acute flare management.

💊

Amitriptyline

Endep® · Tryptanol® · Trepiline®

Adult dose 10 mg nocte, titrate to 25–75 mg nocte over 2–4 weeks

Route Oral

Duration Minimum 6–12 weeks trial at effective dose for chronic pain

Renal adjustment No specific adjustment; use with caution

Hepatic adjustment Reduce dose; avoid in severe impairment

PBS status ✔ PBS General Benefit

Notes Neuropathic pain agent — useful for chronic LBP with neuropathic component. Dual benefit if comorbid depression/anxiety. Advise regarding sedation, dry mouth, constipation, weight gain. Avoid in patients >65 (Beers list) — consider duloxetine as alternative.

💊

Duloxetine

Cymbalta®

Adult dose 30 mg PO daily for 1 week, then 60 mg PO daily

Route Oral

Duration Minimum 8–12 weeks at therapeutic dose

Renal adjustment Avoid if eGFR <30 mL/min

Hepatic adjustment Contraindicated in severe hepatic impairment

PBS status 🔶 PBS Authority Required (for major depressive disorder; pain indication may require private script)

Notes SNRI with evidence for chronic musculoskeletal pain. TGA-approved for chronic musculoskeletal pain. Preferred over amitriptyline in patients >65 years. Dual benefit for comorbid depression. Nausea is common initial side effect — start low.

🚨

Opioids and low back pain: There is no evidence supporting opioid use for non-specific LBP. Opioids carry significant risk of harm including dependence, overdose, opioid-induced hyperalgesia, and increased disability. The RACGP, ACSQHC, and NPS MedicineWise recommend against prescribing opioids for LBP in almost all circumstances. If considered at all, use only short-term (days, not weeks), at lowest effective dose, with clear treatment goals, and with an exit strategy.

Non-Pharmacological Therapies

Therapy	Evidence Level	Recommendation
Continued activity / avoiding bed rest	Strong	Recommend — cornerstone of management. Encourage normal activities and work as tolerated.
Structured exercise / physiotherapy	Strong	Recommend for acute and chronic LBP. Individualised program (core stability, general fitness, graded activity). GP Management Plan + Team Care Arrangement enables Medicare-subsidised allied health visits (MBS items 721, 723).
Spinal manipulation / mobilisation	Moderate	May be considered for short-term relief in acute LBP. Best combined with active exercise. Performed by physiotherapist, osteopath, or chiropractor.
Cognitive behavioural therapy (CBT)	Strong	Recommend for chronic LBP, especially when yellow flags present. Addresses pain beliefs, catastrophising, fear-avoidance.
Pain neuroscience education	Moderate–Strong	Reframes pain understanding; reduces catastrophising. Explain: pain is an output of the brain, not always proportional to tissue damage. Increasingly integrated into Australian physiotherapy practice.
Heat therapy (superficial)	Moderate	Modest benefit for acute LBP. Low cost, low risk. Heat wraps, warm baths.
Acupuncture	Low–Moderate	May provide modest short-term benefit in chronic LBP. Consider as adjunct. Not a substitute for active exercise.
TENS	Low	Insufficient evidence for routine recommendation. May provide temporary symptom relief in some individuals.
Traction / ultrasound / laser	Low / Insufficient	Not recommended. Classified as low-value interventions by Choosing Wisely Australia.

Referral Indications

Emergency referral (via ED): Cauda equina syndrome; suspected epidural abscess with neurological deficit; major motor deficit (foot drop, bilateral weakness)
Urgent spinal surgery referral: Progressive neurological deficit; confirmed tumour/compression on MRI; worsening radiculopathy with motor deficit
Rheumatology referral: Suspected axial spondyloarthritis; inflammatory back pain in young adult; HLA-B27 positive with clinical features
Pain medicine / multidisciplinary pain service: Chronic LBP (>3 months) not responding to primary care management; opioid dependence; significant yellow flags; need for multidisciplinary rehabilitation
Psychology / mental health referral: Comorbid depression/anxiety; significant catastrophising or fear-avoidance; need for CBT or acceptance and commitment therapy (ACT)

Special Populations

🤰

Pregnancy

Low back pain / pelvic girdle pain

Affects 50–80% of pregnancies. Lumbopelvic pain (sacroiliac joint, pubic symphysis) is more common than purely lumbar. Often begins in 2nd trimester.

Paracetamol — first-line

Safe in pregnancy. 500–1000 mg PO every 4–6 hours; max 4 g/day.

NSAIDs — AVOID

Contraindicated in 3rd trimester (risk of premature closure of ductus arteriosus, oligohydramnios). Use with caution in 1st trimester (possible miscarriage risk). Avoid if possible throughout.

Management

Pelvic support belt; physiotherapy (lumbopelvic stabilisation exercises); prenatal yoga; sleeping with pillow between knees; warm (not hot) compresses. Referral to women's health physiotherapist.

👶

Paediatrics

Low back pain in children

Uncommon before puberty (~1–3% of children). Back pain in a child <12 years is a red flag until proven otherwise — always investigate.

Consider

Scheuermann's disease (thoracic kyphosis); spondylolysis / spondylolisthesis (gymnasts, cricket fast bowlers); discitis; osteomyelitis; malignancy (leukaemia, Ewing sarcoma, osteosarcoma); inflammatory arthritis; vertebral fracture (sports injury).

Analgesia

Paracetamol 15 mg/kg every 4–6 hours. Ibuprofen 5–10 mg/kg TDS for short course if needed. Avoid opioids in paediatric populations.

Imaging

Low threshold for imaging in paediatric back pain. MRI preferred (no radiation). If pars defect suspected, SPECT-CT or MRI. Inflammatory markers (ESR, CRP) essential.

👴

Elderly (≥65 years)

Common causes

Degenerative spinal stenosis; osteoporotic vertebral compression fractures; spondylolisthesis; polymyalgia rheumatica (proximal stiffness — distinguish from LBP); AAA (male >65 — screen).

Analgesia

Paracetamol first-line. NSAIDs use with extreme caution — high GI bleed and renal risk (>65 years). If NSAIDs necessary: naproxen + PPI, shortest course possible. Avoid amitriptyline (Beers criteria — anticholinergic burden). Consider duloxetine as alternative for chronic pain.

Opioids

Avoid — falls risk, cognitive impairment, constipation, respiratory depression. If absolutely necessary, lowest dose, short duration, avoid tramadol (seizure risk, serotonin syndrome). Monitor closely.

Vertebral fracture

If suspected: plain X-ray → DEXA → osteoporosis treatment (denosumab, zoledronic acid). Vertebroplasty/kyphoplasty for refractory pain — evidence limited. Assess falls risk.

🫘

Renal Impairment

NSAIDs — caution

Avoid if eGFR <30 mL/min. Risk of acute kidney injury, fluid retention, hyperkalaemia. If eGFR 30–60, use lowest dose for shortest duration and monitor renal function.

Paracetamol

Generally safe; no specific dose adjustment required. Preferred analgesic in CKD.

Gabapentin / pregabalin

If neuropathic pain component present — dose reduction required in CKD. Gabapentin: start 100 mg after dialysis. Pregabalin: dose adjust to eGFR. See PBS authority criteria.

🫁

Hepatic Impairment

Paracetamol

Max 2 g/day in chronic liver disease. Avoid in severe hepatic impairment (Child-Pugh C). Preferred analgesic in most hepatic conditions at reduced dose.

NSAIDs

Avoid in severe hepatic impairment — risk of GI bleeding, fluid retention, hepatorenal syndrome. Use with caution in mild–moderate impairment.

Duloxetine

Contraindicated in severe hepatic impairment. Avoid. Consider amitriptyline at reduced dose or gabapentin as alternatives for neuropathic component.

🛡️

Immunocompromised

High vigilance

Immunocompromised patients (HIV, transplant, biologics, chemotherapy, chronic corticosteroids) are at significantly increased risk of spinal infection (osteomyelitis, discitis, epidural abscess) and atypical organisms. A low threshold for MRI and blood cultures is essential.

Infectious differential

Consider Staphylococcus aureus (most common), Mycobacterium tuberculosis (particularly in migrants from endemic areas and Indigenous Australians in some communities), Brucella, fungal infections (coccidioidomycosis, histoplasmosis).

Consult infectious diseases

Early involvement of infectious diseases team is recommended for suspected spinal infection in immunocompromised hosts.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a significantly higher burden of musculoskeletal conditions, including low back pain, compared with non-Indigenous Australians. The AIHW reports that musculoskeletal conditions are among the top five chronic conditions contributing to the health gap between Indigenous and non-Indigenous Australians.

Higher prevalence & severity

Aboriginal and Torres Strait Islander Australians experience LBP at approximately 1.3–1.5 times the rate of non-Indigenous Australians, with greater associated disability and impact on daily function. Pain tends to present at a younger age and is more likely to become chronic.

Comorbidity burden

Higher rates of diabetes, renal disease, cardiovascular disease, obesity, and mental health conditions compound the impact of LBP and complicate management. Chronic disease burden reduces capacity for physical activity, a key component of LBP management.

Remote & rural access

Many Aboriginal and Torres Strait Islander Australians live in remote or very remote areas with limited access to physiotherapy, rheumatology, pain medicine, and imaging services. Specialist wait times may be months. Telehealth (MBS item 99210 for GP video consultations) and fly-in/fly-out allied health services partially address gaps but remain insufficient.

Cultural safety

Healthcare interactions must be culturally safe. Many Aboriginal and Torres Strait Islander people prefer to be seen by an Aboriginal Health Worker or Aboriginal Health Practitioner. Yarning-based consultations, which allow patients to tell their story in their own time and way, build trust and improve disclosure of psychosocial factors (yellow flags). Validate the patient's pain experience and avoid dismissal.

Yellow flags & psychosocial context

Intergenerational trauma, grief and loss, social determinants of health (housing, employment, education), and systemic racism are significant contributors to chronic pain and disability. Fear-avoidance may present differently — lack of safe spaces for exercise, not just fear of movement. Screen for social and emotional wellbeing using culturally validated tools (e.g., SEWB measures).

Opioid-related harm

Aboriginal and Torres Strait Islander Australians are disproportionately prescribed opioids for chronic non-cancer pain, contributing to opioid-related morbidity and mortality. Culturally appropriate opioid stewardship, non-pharmacological alternatives, and connection to Aboriginal Community Controlled Health Organisations (ACCHOs) for holistic pain management are essential.

Infection considerations

Spinal tuberculosis, while rare overall, should be considered in Aboriginal and Torres Strait Islander patients with chronic back pain, particularly in remote Northern Territory and Queensland communities. Invasive Group A Streptococcus (iGAS) and skin infections (scabies, impetigo — risk for bacteraemia) are more prevalent and may lead to haematogenous seeding of the spine.

Community-based approaches

ACCHOs are the preferred model of care for chronic disease management, including LBP. Programs such as the Healthy Living Program, Good Food, Deadly Choices, and community-based exercise programs provide culturally safe environments for activity-based management. Rheumatic heart disease (RHD) is more common and may cause referred pain — cardiac screen may be indicated in some contexts.

ℹ️

Medicare-funded allied health: Under a GP Management Plan (GPMP, MBS item 721) and Team Care Arrangement (TCA, MBS item 723), Aboriginal and Torres Strait Islander patients are entitled to up to Medicare-subsidised allied health services per year (including physiotherapy, exercise physiology, psychology). This is critical for accessing active management of LBP. Bulk-billing practices and ACCHOs maximise access.

📚 References

1. Australian Commission on Safety and Quality in Health Care (ACSQHC). Clinical Care Standard: Low Back Pain. Sydney: ACSQHC; 2022.
2. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 9th ed. Melbourne: RACGP; 2018.
3. Australian Institute of Health and Welfare (AIHW). Musculoskeletal conditions in Australia. AIHW Cat. no. PHE 254. Canberra: AIHW; 2023.
4. Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;391(10137):2356–2367.
5. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478–491.
6. Brinjikji W, Luetmer PH, Comstock B, et al. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. Am J Neuroradiol. 2015;36(4):811–816.
7. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–ii44.
8. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017;389(10070):736–747.
9. Traeger AC, Hubscher M, Henschke N, et al. Effect of primary care-based education on reassurance in patients with acute low back pain: systematic review and meta-analysis. JAMA Intern Med. 2015;175(5):733–743.
10. National Health and Medical Research Council (NHMRC). National Statement on Ethical Conduct in Human Research. Canberra: NHMRC; 2023 (updated). [Relevant to Indigenous health research guidelines informing culturally safe care.]
11. Buchbinder R, van Tulder M, Öberg B, et al. Low back pain: a call for action. Lancet. 2018;391(10137):2384–2388.
12. Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet. 2011;378(9802):1560–1571.
13. NPS MedicineWise. Analgesic choices in persistent pain: NPS MedicineWise prescriber update. Sydney: NPS MedicineWise; 2022.
14. Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991.
15. Australian Bureau of Statistics (ABS). National Aboriginal and Torres Strait Islander Health Survey. Cat. no. 4715.0. Canberra: ABS; 2019.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).